Syndax Pharma Files 2024 Executive Compensation Details
Ticker: SNDX · Form: DEF 14A · Filed: Apr 1, 2025 · CIK: 1395937
| Field | Detail |
|---|---|
| Company | Syndax Pharmaceuticals Inc (SNDX) |
| Form Type | DEF 14A |
| Filed Date | Apr 1, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, proxy-statement, equity-awards
TL;DR
Syndax Pharma dropped its 2024 exec comp filing - check out Metzger & Morrison's equity awards.
AI Summary
Syndax Pharmaceuticals Inc. filed a DEF 14A on April 1, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes information on equity awards granted to key personnel such as Michael A. Metzger and Briggs W. Morrison, with specific vesting dates and valuation changes reported.
Why It Matters
This filing provides transparency into how Syndax Pharmaceuticals compensates its top executives, which can influence investor perception and executive decision-making.
Risk Assessment
Risk Level: low — This is a routine annual filing providing information on executive compensation and does not indicate any immediate financial or operational risks.
Key Numbers
- 2024 — Fiscal Year End (Reporting period for executive compensation details.)
- 20250401 — Filing Date (Date the DEF 14A was submitted to the SEC.)
Key Players & Entities
- Syndax Pharmaceuticals Inc (company) — Filer
- Michael A. Metzger (person) — Executive
- Briggs W. Morrison (person) — Executive
- 0000950170-25-048472 (filing_id) — Accession Number
FAQ
What is the primary purpose of a DEF 14A filing?
A DEF 14A filing, also known as a Definitive Proxy Statement, is used to solicit proxies from shareholders for an upcoming annual or special meeting of shareholders. It contains detailed information about matters to be voted on, including executive compensation, director nominations, and other corporate governance issues.
Who are the key individuals mentioned in relation to executive compensation for Syndax Pharmaceuticals Inc. in this filing?
The filing mentions Michael A. Metzger and Briggs W. Morrison in the context of executive compensation and equity awards for the fiscal years 2023 and 2024.
What specific types of compensation are detailed for the executives?
The filing details changes in fair value of equity awards granted and vested, as well as outstanding and unvested equity awards for both 'PeoMember' (Principal Executive Officer) and 'NonPeoNeoMember' (Non-Principal Executive Officer, Non-Employee Officer).
What is the fiscal year end for Syndax Pharmaceuticals Inc.?
The fiscal year end for Syndax Pharmaceuticals Inc. is December 31st.
What is the SIC code for Syndax Pharmaceuticals Inc.?
The Standard Industrial Classification (SIC) code for Syndax Pharmaceuticals Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 1, 2025 by Michael A. Metzger regarding Syndax Pharmaceuticals Inc (SNDX).